Semaglutide Access for Indigenous Australians: Equity, Cost, and Real-World Barriers

Cardiovascular disease (CVD) represents a critical health challenge globally, with a particularly severe and disproportionate impact on Aboriginal and Torres Strait Islander peoples in Australia, contributing significantly to health disparities and reduced life expectancy. Semaglutide, a potent glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated remarkable efficacy not only in managing type 2 diabetes and obesity but also in providing substantial cardiovascular benefits, including a reduction in major adverse cardiovascular events. Despite its proven clinical advantages, the specific systemic barriers, including the prohibitive cost and complex real-world implementation hurdles, that prevent equitable access to Semaglutide for Aboriginal and Torres Strait Islander communities remain underexplored and unaddressed. This gap in understanding hinders effective policy development and healthcare delivery strategies.